Krsnaa Diagnostics Limited has informed the Exchange about Investor Presentation
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krsnaa Diagnostics reported strong FY25 results with revenue growing 16% YoY to ₹7,172 million, EBITDA up 34% to ₹1,958 million, and PAT up 37% to ₹776 million. EBITDA margin expanded by 370 basis points to 27%, reflecting improved operational efficiency and higher patient footfalls. Q4FY25 also showed healthy growth with revenue up 12% to ₹1,861 million and EBITDA up 21% to ₹542 million. The company shared growth targets, aiming to scale CT centres from 143 to 180, collection centres from 3,478 to 5,000, and expand its retail network from 250 to 700 centres by FY27E. Expansion is driven by a public-private partnership (PPP) model, retail foray in Maharashtra, Punjab, Assam and Odisha, and aggressive cost leadership with prices 71-95% lower than competitors.
The strong margin expansion and multi-year growth roadmap could positively influence investor sentiment. However, significant capex for expansion and a rising debt position (current borrowings up to ₹1,470 mn from ₹1,012 mn) may be points to watch.